Prenatal genetic testing 1: screening tests.
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
10
9
2022
medline:
4
11
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Prenatal genetic testing can be divided into two categories: screening and diagnostic. This article will focus on reviewing prenatal genetic screening tests. Cell-free DNA (cfDNA) is a new prenatal genetic screening test with a high degree of accuracy for identifying certain genetic conditions like trisomy 21, 18, and 13. However, cfDNA has also been applied in the screening of other genetic conditions without similar research support. Prenatal genetic screening evaluates at risk pregnancies - including both carrier screening, which can be done at any point in a person's life, and aneuploidy screening, which is done during pregnancy. Within screening, there is a new noninvasive technology that has revolutionized prenatal screening called cfDNA testing. Compared to previous methods, this technology is easier to administer and more accurate for certain genetic conditions. However, cfDNA has also been applied to test for less common genetic conditions without efficacious research support. In this time of expansion in genetic testing, it is important that providers educate themselves on the research support behind each type of genetic test. It is vital that professional organizations continuously update their testing approach to match these rapidly evolving technologies and the patient population they serve.
Identifiants
pubmed: 36081381
doi: 10.1097/MOP.0000000000001172
pii: 00008480-202212000-00005
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
544-552Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lea D, Kaphingst K, Bowen D, et al. Communicating genetic and genomic information: health literacy and numeracy considerations. Public Health Genomics 2011; 14:279–289.
Gregg A, Edwards J. Prenatal genetic carrier screening in the genomic age. Semin Perinatol 2018; 42:303–306.
Gregg A. Expanded carrier screening. Obstet Gynecol Clin North Am 2018; 45:103–112.
The American College of Obstetricians and Gynecologists (n.d.). Prenatal genetic screening tests. Available at: https://www.acog.org/womens-health/faqs/prenatal-genetic-screening-tests [retrieved 1 May 2022].
Gregg A, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021; 23:1793–1806.
Edwards J, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine—points to consider. Obstet Gynecol 2015; 125:653–662.
Committee Opinion No. 691. Carrier screening for genetic conditions. Obstet Gynecol 2017; 129:41–55.
Westemeyer M, Saucier J, Wallace J, et al. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach. Genet Med 2020; 22:1320–1328.
Committee Opinion No. 690. Carrier screening in the age of genomic medicine. Obstet Gynecol 2017; 129:e35–340.
Bethesda Technical Standards and Guidelines for CFTR Mutation Testing. American College of Medical Genetics Standards and Guidelines for Clinical Genetics Laboratories. ACMG; 2011.
Deignan J, Astbury C, Cutting G, et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020; 22:1288–1295.
Watson M, Cutting G, Desnick R, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics Mutation Panel. Genet Med 2004; 6:387–391.
Bethesda. 2015 Patient registry annual data report. Cystic Fibrosis Foundation; 2016.
Zhang J, Wang Y, Ma D, et al. Carrier screening and prenatal diagnosis for spinal muscular atrophy in 13,069 Chinese pregnant women. J Mol Diagn 2020; 22:817–822.
ACOG Committee Opinion No. 410. Ethical issues in genetic testing. Obstetr Gynecol 2008; 111:1495–1502.
Wald N, Bestwick J. Prenatal reflex DNA screening for down syndrome: enhancing the screening performance of the initial first trimester test. Prenatal Diagn 2016; 36:328–331.
U.S. National Library of Medicine. Unity carrier screen − clinical test − NIH genetic testing registry (GTR) − NCBI. National Center for Biotechnology Information. n.d.
Westin E, Tsao D, Atay O, et al. Validation of single-gene noninvasive prenatal testing for sickle cell disease. Am J Hematol 2022; 97:E270–E273.
Rink B, Norton M. Screening for fetal aneuploidy. Semin Perinatol 2016; 40:35–43.
Screening for Fetal Chromosomal Abnormalities. ACOG Practice Bulletin No. 4Am Coll Obstetr Gynecol 2020; 136:e48–e67.
Wald N, Cuckle H, Brock J, et al. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet 1977; 1:1323–1332.
Wapner R, Thom E, Simpson J, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349:1405–1413.
Malone F, Canick J, Ball R, et al. First-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001–2011.
Carlson L, Vora N. Prenatal Diagnosis: screening and diagnostic tools. Obstet Gynecol Clin N Am 2017; 44:245–256.
Hu T, Tian T, Zhang Z, et al. Prenatal chromosomal microarray analysis in 2466 fetuses with ultrasonographic soft markers: a prospective cohort study. Am J Obstet Gynecol 2021; 224:516e1–e16.
Foundation T. Nuchal translucency scan: FMF certification. Welcome to the Fetal Medicine Foundation. n.d.
Karim J, Roberts N, Salomon L, Papageorghiou A. Systematic review of first-trimester ultrasound screening for detection of fetal structural anomalies and factors that affect screening performance. Ultrasound Obstet Gynecol 2017; 50:429–441.
Gregg A, Skotko B, Benkendorf J, et al. Noninvasive prenatal screening for fetal aneuploidy 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med 2016; 15:395–398.
Grace M, Hardisty E, Dotters-Katz S, et al. Cell-free DNA screening: complexities and challenges of clinical implementation. Obstet Gynecol Surv 2016; 71:477–487.
Shaw J, Scotchman E, Chandler N, Chitty L. Preimplantation genetic testing: noninvasive prenatal testing for aneuploidy, copy-number variants and single-gene disorders. Reproduction 2020; 160:A1–A11.
Gil M, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2017; 50:302–314.
Dugoff L, Koelper N, Chasen S, et al. Factors that affect cell-free DNA fetal fraction in twin gestations. Am J Obstet Gynecol 2022; 226:S437–S438.
Gil M, Galeva S, Jani J, et al. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of the fetal medicine foundation results and meta-analysis. Ultrasound Obstet Gynecol 2019; 53:734–742.
Galeva S, Gil M, Konstantinidou L, et al. First-trimester screening for trisomies by cfDNA testing of maternal blood in singleton and twin pregnancies: factors affecting test failure. Ultrasound Obstet Gynecol 2019; 53:804–809.
Bedei I, Wolter A, Weber A, et al. Chances and challenges of new genetic screening technologies (NIPT) in prenatal medicine from a clinical perspective: a narrative review. Genes 2021; 12:501.